ChromoCure Expands Capacity: Recent Mayo Clinic Findings Encourage Aneuploidy Research Worldwide
2010年4月13日 - 9:30PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) cites a major worldwide
increase in the research of the aneuploidy theory of cancer. The
company has increased its operational capabilities through its
recently signed Technology Exchange and Collaboration Agreement
with Genome Research Group.
The Mayo Clinic findings that confirmed aneuploidy as a cause of
cancer published in the December 2009 Cancer Cell journal have
spurred research in an increasing number of respected research
universities and institutions, all of which have published reports
in 2010; including:
- Yunnan Normal University.
- University College London, Department of Pathology
- Hokkaido University
- Oslo University Hospital
- Universitat Autonoma de Barcelona
- Dartmouth University, Department of Biochemistry
- Tel Aviv University, Medical Department
- University of South Florida, H. Lee Moffitt Cancer Center
University of Pune
- University of Texas, M. D. Anderson Cancer Center
The Company recently announced its Joint Venture and Technology
Sharing Agreement with Genome Research Group. GRG's advanced
Therapeutic Modeling Protocols, together with ChromoCure's landmark
Chromosomal Scanning Technology, further strengthens the Company's
leadership in Cancer Detection, Therapy and Cure, and puts new
impetus to its groundbreaking Project Boveri: Finding the Cure.
The Company's proprietary Chromosomal Scanner systems have
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. This is superior to other detection approaches presently
relied upon by pathologists, including genetic or protein biomarker
detection.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Chromocure Inc (CE) (その他OTC): 0 recent articles
その他のChromoCure, Inc.ニュース記事